Agenus Inc.

Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on discovering, developing, and delivering immuno-oncology therapies to combat cancer. The company's mission is to mobilize the body's immune system to fight cancer and improve patient outcomes, aiming to expand the population of patients who can benefit from immunotherapy through innovative combination approaches.

Agenus's comprehensive pipeline includes a range of immunological agents such as checkpoint modulators, patient-specific anti-cancer vaccines (Prophage series), and adjuvants (QS21-Stimulon). Its lead programs, botensilimab (BOT) and balstilimab (BAL), are next-generation immunotherapy candidates in advanced clinical trials, demonstrating activity across various cancer types, including those historically resistant to checkpoint inhibition. The company is actively pursuing a Phase 3 BATTMAN trial for metastatic colorectal cancer with its BOT+BAL combination.

Co-founded in 1994 by Garo H. Armen, who serves as Chairman and CEO, Agenus has recently engaged in significant strategic activities. In January 2026, the company finalized a collaboration with Zydus Lifesciences, which involved Zydus acquiring Agenus's biologics manufacturing facilities and gaining exclusive rights to develop and commercialize the BOT+BAL combination in India and Sri Lanka. Agenus also reported positive Phase II data in April 2026 for its combination therapy in PD-1 refractory gastroesophageal cancer and is slated to present Phase 2 botensilimab data in advanced cutaneous melanoma at ASCO 2026, underscoring its ongoing commitment to advancing novel cancer treatments.